Shopping Cart
- Remove All
- Your shopping cart is currently empty
TAPI-2 is a broad-spectrum inhibitor of MMP (IC50: 20 μM), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder | |
100 mg | Inquiry | Backorder |
Description | TAPI-2 is a broad-spectrum inhibitor of MMP (IC50: 20 μM), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM). |
Targets&IC50 | MMP:1.5 nM (Ki), MMP:20 μM |
In vitro | TAPI-2 bounds to h-meprin with IC50 20 μM for h-meprin β subunit and 1.5 nM for h-meprin α subunit. Generally, h-meprin α is inhibited more strongly than the β subunit [1]. Without affecting ADAM17 expression, TAPI-2 dramatically decreases the protein levels of NICD and its downstream target HES-1 in both HCP-1 and HT29 cells. Moreover, treating cells with TAPI-2 significantly decreases the CSC phenotype by -50% in both CRC cell lines. The dose-dependent effects of TAPI-2 on the sphere formation and protein levels of NICD and HES-1 confirm that the concentration used (20 μM) is within the effective dose range of TAPI-2 (5–40 μM) [2]. |
Alias | TAPI-2 |
Molecular Weight | 415.53 |
Formula | C19H37N5O5 |
Cas No. | 187034-31-7 |
Relative Density. | 1.127 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (48.13 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.